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Abstract
 
Invasion of erythrocytes by 
 
Plasmodium
 
 merozoites is an intricate process involving multiple re-
ceptor-ligand interactions. The glycophorins and an unknown trypsin sensitive factor are all
erythrocyte receptors used during invasion by the major human pathogen 
 
Plasmodium falci-
parum
 
. However, only one erythrocyte receptor, Glycophorin A, has a well-established cognate
parasite ligand, the merozoite protein erythrocyte binding antigen-175 (EBA-175). The in-
volvement of several other parasite proteins during invasion have been proposed, but no direct
evidence links them with a specific invasion pathway. Here we report the identification and
characterization of 
 
P. falciparum
 
 normocyte binding protein 1 (PfNBP1), an ortholog of 
 
Plasmo-
 
dium vivax
 
 reticulocyte binding protein-1. PfNBP1 binds to a sialic acid dependent trypsin-
resistant receptor on the erythrocyte surface that appears to be distinct from known invasion
receptors. Antibodies against PfNBP1 can inhibit invasion of trypsinized erythrocytes and two
 
P. falciparum
 
 strains that express truncated PfNBP1 are unable to invade trypsinized erythro-
cytes. One of these strain, 7G8, also does not invade Glycophorin B–negative erythrocytes.
PfNBP1 therefore defines a novel trypsin-resistant invasion pathway and adds a level of com-
plexity to current models for 
 
P. falciparum
 
 erythrocyte invasion.
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Introduction
 
The clinical symptoms and pathology associated with ma-
laria occur during the asexual erythrocytic phase of the
 
Plasmodium
 
 life cycle. 
 
Plasmodium
 
 merozoites, ovoid cells
with an apical prominence at one end, invade erythro-
cytes, wherein they multiply and eventually rupture their
host cell, releasing newly formed merozoites to initiate a
new round of invasion. Erythrocyte invasion is a complex
and dynamic process, involving both a reversible attach-
ment and reorientation phase and an irreversible commit-
ment and invasion phase. Yet although erythrocyte inva-
sion has been extensively described at the ultrastructural
level, the molecular details and the individual receptor–
ligand interactions involved at each step are only begin-
ning to be understood.
In the case of the major human malaria pathogen, 
 
Plas-
modium falciparum,
 
 several erythrocyte invasion receptors
have been identified. The relative importance of each re-
ceptor is clearly strain dependent. Whether cultured exten-
sively in vitro or collected directly from patients in the
field, isolates can differ markedly in which receptors they
are able to use (1, 2). Certain strains are able to switch be-
tween different pathways in a genetically stable manner,
suggesting that 
 
P. falciparum
 
 can functionally adapt depend-
ing upon the available host cell receptor(s) (3). Treatment
of erythrocytes with neuraminidase reduces or eliminates
invasion in many 
 
P. falciparum
 
 strains. The closely related
Glycophorins A and B and the minor glycophorins, C and
D, have all been proposed to contribute to sialic-acid de-
pendent invasion (4–7). Some strains invade erythrocytes
that lack glycophorins by using a sialic acid–independent,
trypsin-sensitive receptor(s), but extensive searching using
well characterized mutant RBCs has not revealed the iden-
tity of this receptor, which is often referred to as Receptor
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X (8–10). Receptors other than the glycophorins and Re-
ceptor X may also be involved in invasion.
On the parasite side, many 
 
P. falciparum
 
 proteins have
been proposed to be important for invasion, largely because
of where and when they are expressed in the merozoite.
However, Glycophorin A is the only known erythrocyte
invasion receptor to have a clearly defined parasite ligand,
erythrocyte binding antigen-175 (EBA-175),
 
*
 
 a 
 
P. falci-
parum
 
 homologue of the human malaria 
 
Plasmodium vivax
 
and simian malaria 
 
Plasmodium knowlesi
 
 Duffy binding pro-
teins (11–13). A specific domain of EBA-175 has been
shown to bind Glycophorin A in vitro, requiring both
sialic acid and the peptide backbone for efficient adhesion
(14). Despite a high degree of homology between Glyco-
phorins A and B, EBA-175 does not mediate binding to
Glycophorin B, nor is it the ligand for the sialic acid–inde-
pendent Receptor X (1, 15, 16). More recently, a para-
logue of EBA-175, termed BAEBL, has been proposed to
bind to Glycophorins C or D (17). Many 
 
P. falciparum
 
ligands clearly remain to be identified.
Merozoites of the other major human malaria, 
 
P. vivax
 
,
have an additional level of complexity in their invasion
process, as unlike 
 
P. falciparum
 
, they only invade reticulo-
cytes, a developmentally immature minor subpopulation of
the erythrocyte pool. The 
 
P. vivax
 
 reticulocyte binding
proteins, PvRBP1 and PvRBP2, are expressed apically in
merozoites as a complex, bind specifically to reticulocytes,
and have been proposed to select reticulocytes for invasion
(18–20). Two homologs of PvRBP2 have recently been
identified in 
 
P. falciparum
 
, and are believed to be function-
ally important for targeting all RBCs for invasion by this
species (21, 22). Additionally, a family of 235 kD rhoptry
proteins of the rodent malaria 
 
Plasmodium yoelii
 
, are related
to PvRBP2 (20, 23). These proteins adhere to mouse
erythrocytes and monoclonal antibodies raised against them
can also inhibit invasion (24, 25).
Here we present the identification and characterization
of a 
 
P. falciparum
 
 ortholog of PvRBP1, normocyte binding
protein-1 (PfNBP1). The PfNBP1 protein is expressed at
the invasive apical end of merozoites and appears to form a
complex with at least one of the 
 
P. falciparum
 
 PvRBP2 ho-
mologs. PfNBP1 binds to erythrocytes in a sialic acid–
dependent but trypsin-resistant manner and does not ap-
pear to bind to either Glycophorin A, B, C, or D, or
Receptor X. Specific antisera against PfNBP1 and the 
 
P.
falciparum
 
 PvRBP2 homologs inhibit merozoite invasion
into trypsinised erythrocytes. Furthermore, two 
 
P. falci-
parum
 
 strains that express truncated PfNBP1 are unable to
invade trypsinised cells. We therefore propose that PfNBP1
and the 
 
P. falciparum
 
 homologs of PvRBP2 are involved in
a trypsin-resistant invasion pathway. These findings expand
our knowledge of 
 
P. falciparum
 
 invasion and introduce an-
 
other potential target for receptor-mediated blockade and
vaccine-induced interventions against this important hu-
man malaria parasite species.
 
Materials and Methods
 
Parasites: Culture and Strains.
 
The FVO strain of 
 
P. falciparum
 
was obtained from a parasite line adapted to 
 
Aotus
 
 monkeys and
established in in vitro culture in human O
 
 
 
 erythrocytes (26, 27).
 
P. falciparum
 
 strains 7G8, HB3, and Dd2 were obtained from the
Malaria Research and Reference Reagent Resource Center,
strain 3D7 from WRAIR, and were cultured in human O
 
 
 
erythrocytes.
 
Nucleic Acid and Sequence Analysis.
 
Databank BLAST-based
searches were conducted at the Sanger Center internet site at
http://www.sanger.ac.uk and at PlasmoDB at http://plasmodb.
org. Sequence data for 
 
P. falciparum
 
 chromosome 4 was ob-
tained from http://www.sanger.ac.uk/Projects/P_falciparum/.
Sequencing of 
 
P. falciparum
 
 chromosome 4 was accomplished as
part of the Malaria Genome Project with support by The
Wellcome Trust. 
 
P. falciparum
 
 genomic DNA (gDNA) was pre-
pared as described (18). RNA was prepared from mature schiz-
onts using ToTALLY RNA Isolation Kit (Ambion) and treated
with RNAase-free DNAase (Ambion). cDNA was synthesized
and purified using a 5
 
 
 
 RACE kit (GIBCO BRL) and the
gene-specific primer 5
 
 
 
-GGATATCAATAAATTTGGCAG-3
 
 
 
.
Nested PCR was performed using the provided Abridged An-
chor primer as a forward primer and the gene specific primer in
the primary reaction, then forward primer 5
 
 
 
-GCAAAGGTG-
GATTTTCTGC-3
 
 
 
 and reverse primer 5
 
 
 
-CGAATGGAT-
TCTAATCATTTCCAG-3
 
 
 
 in the secondary reaction. PCR
was performed using EXPAND High Fidelity Kit (Roche) or Pfu
Turbo Polymerase (Stratagene) and products cloned using a TA
cloning kit (Invitrogen) or a PCR-Script AMP cloning kit (Strat-
agene). DNA sequencing was performed using a BigDye Termi-
nator Cycle Sequencing v2.0 Ready Reaction Kit (ABI Prism)
on a 3100 Genetic Analyzer (ABI Prism). Gene and deduced
protein sequences were analyzed and compared using the
MacVector 6.5.3 DNA/Protein analysis module (Oxford Molec-
ular). Amino acid alignments were performed using CLUSTAL
X (28). Phylogenetic and molecular evolutionary analyses of
PfNBP1 and other members of the PvRBP-Like (RBL) super-
family was accomplished using MEGA version 2.1 (29).
 
Antisera, Immunoblots, and Immunofluorescence.
 
A rabbit antise-
rum was raised against a GST fusion protein using the pGEX sys-
tem (Amersham Pharmacia Biotech). A GST fusion protein was
made by amplifying 
 
P. falciparum
 
 FVO gDNA, with primers
5
 
 
 
-GACGATATATACCATGCTGAT-3
 
 
 
 and 5
 
 
 
-TTGTGAT-
ATATCTTGAAGG-3
 
 
 
. Fusion protein was purified from 
 
Esche-
richia coli
 
 using standard methodologies on glutathione-sepharose
4B (Amersham Pharmacia Biotech) and injected into New
Zealand White rabbits using Freund’s complete and incomplete
adjuvants. EBA-175 antiserum was obtained from the Malaria
Research and Reference Reagent Resource Center. For immu-
noblots, protein samples made by boiling partially purified late
segmented schizonts in reducing SDS-PAGE sample buffer were
run on 6% polyacrylamide gels (37.5:1 acrylamide:bis), transferred
to nitrocellulose membranes (Schleicher & Schuell), probed with
primary antisera, and developed with an enhanced chemolu-
minescence (ECL) kit (Amersham Pharmacia Biotech). The anti-
Glycophorin A and B antiserum was obtained from Sigma-
Aldrich. Immunofluorescence assays (IFAs) were performed on
 
*
 
Abbreviations used in this paper:
 
 DBL, Duffy binding like; EBA, erythro-
cyte binding assay; EBA-175, erythrocyte binding antigen-175; PfNBP,
 
Plasmodium falciparum
 
 normocyte binding protein; PvRBP, 
 
Plasmodium
vivax
 
 reticulocyte binding protein; TMD, transmembrane domain; ORF,
open reading frame. 
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air-dried thin smears of 
 
P. falciparum
 
 (FVO strain) infected eryth-
rocytes, with secondary antibodies from Zymed laboratories
(FITC anti–rabbit) or Jackson ImmunoResearch Laboratories
(Cy3 anti–mouse). Both secondary antibodies had been cross-
adsorbed against sera from other species to minimize cross-reac-
tivity. Images were merged using Adobe Photoshop 5.0 software.
 
Biosynthetic Radiolabeling and Immunoprecipitation.
 
Biosyn-
thetic radiolabeling of intraerythrocytic parasites with [
 
35
 
S]me-
thionine/cysteine (ICN) was performed at 100 
 
 
 
Ci/ml during in
vitro culture. Labeled schizont-stage parasites were lysed on ice
for 30 min in PBS with 1% NP-40 and standard protease inhibi-
tors added, with occasional vortexing. Lysates were cleared by
centrifugation. Immunoprecipitations were performed as de-
scribed (18).
 
Erythrocyte Binding Assays.
 
Schizont stage parasites were puri-
fied by centrifugation on 40%/60%/70%/80% Percoll/sorbitol
gradients, as described. (30). To make culture supernatants, puri-
fied schizonts were placed back into in vitro culture at 2.5 
 
 
 
 10
 
7
 
parasites/ml and allowed to rupture overnight. Cells were har-
vested by centrifugation and supernatants stored at 
 
 
 
80
 
 
 
C. To
perform erythrocyte binding assays (EBAs), culture supernatant
was rotated with the appropriate erythrocytes at room tempera-
ture for 2 h. Cells were separated from the supernatant by centrif-
ugation through a Dow Corning 550 fluid cushion, and bound
material was separated from cells by incubation in an equal vol-
ume of 5
 
  
 
RPMI at room temperature. Released material was
harvested by centrifugation and analyzed by immunoblotting.
Cryopreserved S-s-U- human erythrocytes and control cells were
obtained from Dr. Marion E. Reid at the New York Blood Cen-
ter, New York, NY.
Reticulocytes were enriched as previously described (31). For
enzymatic treatment, erythrocytes were treated at 1 
 
 
 
 10
 
8
 
 cells/
ml in RPMI with 1 mg/ml trypsin (Calbiochem), 0.025U/ml
neuraminidase (Vibrio cholerae; Roche), or 0.5 mg/ml Pronase
(Calbiochem) at 37
 
 
 
C for 1 h. Cells treated with trypsin were
then washed and treated with 0.5 mg/ml soybean trypsin inhibi-
tor (Sigma-Aldrich) for 15 min at room temperature.
 
Invasion Assays.
 
Schizont stage parasites were purified as
above, and placed into in vitro culture with the appropriate target
erythrocytes. Ring stage parasites were counted following a 12–
20 h incubation. All invasion assays were repeated between two
and ten times, and at least 1,000 erythrocytes counted per assay. If
invasion rates were low, as when enzyme treated cells were used,
up to 4,000 erythrocytes were counted in each assay. IgG was
purified using Affi-Gel Protein A and MAPS II binding reagents
(Bio-Rad Laboratories). After elution from the Protein A col-
umn, IgG was dialyzed against RPMI and added to invasion as-
says at concentrations as described in the text.
 
Results
 
Identification of PfNBP1, a Homologue of PvRBP1.
 
Mem-
bers of the interspecies PvRBP family are high MW
proteins that share a low level of amino acid homology and
structural features, most notably a short exon 1 encoding a
signal sequence followed by a large exon 2 encoding the
bulk of the protein and a single predicted transmembrane
domain (TMD) close to the COOH terminus (18, 20, 21,
32). Antibodies recognizing the NH
 
2
 
-terminal region and a
central domain of PvRBP1 produce immunofluorescence
patterns at the merozoite apical pole in mature schizonts
and free merozoites of 
 
P. knowlesi
 
 and 
 
P. falciparum
 
 similar
 
to those seen in 
 
P. vivax
 
 (data not shown), suggesting
the presence of related proteins in these two species.
TBLASTN searching of the 
 
P. falciparum
 
 genome databases
with selected fragments or the complete PvRBP1 protein
sequence identified several open reading frames (ORFs).
While most corresponded to previously known homologs
of PvRBP2 or spurious hits, one ORF on chromosome 4
(current PlasmoDB ORF 003009) consistently scored
higher (referred to henceforth as 
 
Pfnbp1
 
, as discussed be-
low). There is a short exon and a potential intron of 98 bp
with consensus intron splice sites upstream of this large
ORF. In keeping with members of the PvRBP family, the
short exon 1 encodes a potential signal sequence. PCR on
 
P. falciparum
 
 FVO strain reverse transcribed RNA with
primers flanking the predicted intron amplified a smaller
band than amplified from gDNA (Fig. 1 A). Cloning and
sequencing of the PCR products confirmed the predicted
intron boundaries (Fig. 1 B).
The exon 2 ORF identified in the 
 
P. falciparum
 
 (3D7
strain) database extends for 8.3 kb but does not contain a
COOH-terminal TMD. However, a second ORF of 627
Figure 1. Pfnbp1 shares features with members of the Pvrbp gene fam-
ily. (A) PCR using primers flanking the putative Pfnbp1 intron. Template
was either P. falciparum FVO gDNA (lane 1), cDNA from P. falciparum
FVO RNA (lane 2), or reverse transcription reaction performed in ab-
sence of reverse transcriptase (lane 3). (B) Sequence of the Pfnbp1 inter-
vening sequence and consensus splice sites (arrowed). (C) Diagram show-
ing gene structure and encoded protein features of Pfnbp1 shared by other
PvRBP super family members. The position of the fragment used to raise
antiserum (N1) is also noted. Arrows denote approximate positions of po-
tential frameshift mutations in 3D7 and 7G8 strains. (D) Phylogenetic re-
lationships of the known members of the RBL superfamily as determined
by Neighbor-Joining following a Poisson model with pairwise deletion. 
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bp in another frame immediately downstream of the exon
2 sequence does contain a predicted TMD. Cloning and
sequence analyses of a 2-kb fragment spanning this region
from several 
 
P. falciparum
 
 strains (FVO, HB3, Dd2, and
Malayan Camp K
 
 
 
) indicate that in these strains, the two
coding regions are contiguous as one ORF. Therefore, the
gene is structurally consistent with other members of the
PvRBP/Py235 family with an exon 2 of 
 
 
 
8.9 kb (Fig. 1
C). Thus, the 3D7 strain has a single nucleotide insertion in
a polyadenine sequence that causes premature termination
of the 
 
Pfnbp1
 
 transcript (termination site shown in Fig. 1
C). Other than this mutation, all strains had a very high
level of sequence identity over the regions sequenced, with
the exception of a series of repeated His-Asn residues
near  the predicted TMD, the number of which differs
among the strains (GenBank/EMBL/DDBJ accession nos.
AF411929–AF411933).
Importantly, the 
 
Pfnbp1
 
 locus in most strains shares a
common gene and deduced protein structure with both 
 
P.
vivax
 
 
 
rbps,
 
 the 
 
P. yoelii
 
 
 
p235
 
 genes, and the 
 
P. falciparum rbp2
 
homologs (Fig. 1 C). Analysis of CLUSTAL W alignments
of the predicted PfNBP1 amino acid sequence with the
other members supports this familial relationship, with an
overall level of similarity of 30–35% (identity plus conserva-
tive substitutions). In P. vivax, PvRBP1 and PvRBP2 are
distantly related but do not share any regions of  22%
identity (18, 20). The P. yoelii 235 kD and the previously
identified  P. falciparum PfRBP2-homologs consistently
group in phylogenetic analyses with PvRBP2 rather than
PvRBP1 (21, 22). In contrast, BLASTP searching with the
new P. falciparum protein consistently identifies PvRBP1 as
the top scoring entry. Construction of phylogenetic trees
based on CLUSTAL X alignments and, most impor-
tantly, either Neighbor-Joining (Fig. 1 D) or Maximum
Parsimony analyses supports such an orthologous relation-
ship. PfNBP1 always groups with PvRBP1, whereas the
PfRBP2-Hs, the pseudogene PfRH3 (33), and Py p235 al-
ways form a second grouping. For this reason, we have
chosen to call this protein PfNBP1, for P. falciparum Nor-
mocyte Binding Protein 1, as was originally proposed for
orthologs of the PvRBPs (19), and to conform to the no-
menclature for the PvRBPs, with 1 as a subscript to indicate
the closer relationship with PvRBP1 than PvRBP2. To fol-
low this nomenclature, we propose that the P. falciparum
RBP2 homologs, which we initially called PfRB2-Ha and
–Hb (21), should be renamed PfNBP2a and PfNBP2b and
we will use this format for the rest of the paper.
PfNBP1 Is Located at the Invasive Apical End of Mero-
zoites. A polyclonal PfNBP1 rabbit antiserum was raised
against a polypeptide (N1) encoded by a fragment of the
Pfnbp1 exon 2 (Fig. 1 B). The N1 antiserum showed a
staining pattern by immunofluorescence assay (IFA) on late
schizonts that localized to the apical end of merozoites (Fig.
2 A). Although some discrete focal staining was visible, on
the whole, staining was more widely distributed across the
apex of the merozoite. In several instances, cap-like stain-
ing patterns over the conoid apical process of the merozoite
were observed (arrowed, Fig. 2 A), similar to that described
for PvRBP1 and PvRBP2 (18). By comparison, antisera
against several regions of PfNBP2a and PfNBP2b, includ-
ing the S3 antiserum against a portion of the shared region
of these proteins, localize discretely to the apical end of
merozoites with usually one, but occasionally two, foci in
each merozoite (21; Fig. 2 A).
The PfNBP2a and PfNBP2b distribution has some hall-
marks of localization to the paired rhoptry organelles (char-
acterized by a consistent double dot pattern), but their pat-
terns are most similar to that of the P. falciparum rhoptry
protein Pf240, described as single foci occasionally resolv-
ing into double dots (34). Costaining of late schizonts with
the S3 rabbit antiserum and a mAb recognizing the Pf240
protein showed very similar overlap of staining patterns,
whereas the Pf240 protein staining only partially over-
lapped with a rabbit antiserum raised against EBA-175 (Fig.
2 B, and data not shown). The Pf240 specific mAb local-
Figure 2. PfNBP1 is expressed at the apical end of merozoites. (A) Im-
munofluorescence assays performed on P. falciparum FVO infected eryth-
rocytes, using anti-PfNBP1 (N1) or anti-PfNBP2a and b antisera (S3). S3
antiserum gives an occasional double dot in a single merozoite (arrowed).
N1 staining is broader but defined, with the frequent appearance of apical
cap staining (arrowed). (B) Costaining performed with mouse mAb
(24C6 4F12), which recognizes Pf240, an antigen that localizes to the
neck of the paired rhoptry organelles. Rabbit antisera against PfNBP2a
and b (S3), the microneme protein EBA-175 (175), or PfNBP1 (N1)
were coincubated with this mouse mAb, and FITC anti–rabbit IgG
(green fields) and Cy3 anti–mouse IgG (red fields) secondary antibodies
were used for detection.1575 Rayner et al.
ized the antigen by immuno-electron microscopy to the
“neck” of the rhoptries where the peduncles join in a com-
mon duct immediately below the apical end of the mero-
zoite (34). The precise colocalization of S3 staining with
the Pf240 mAb suggests that PfNBP2a and 2b may also lo-
calize there. In contrast, EBA-175 is located in the micro-
nemes (35), which are at the apical pole but quite distinct
from the rhoptries. As expected given its staining pattern,
the PfNBP1 antiserum shows only partial overlap with the
Pf240 mAb. Thus, whereas PfNBP2a and PfNBP2b may
be restricted to the neck of the rhoptries, PfNBP1 may be
partially located there but is also clearly present in a broader
apical localization.
The P. falciparum PvRBP Homologs Form a Complex. A
390-kD PfNBP1 band is immunoprecipitated with the N1
antisera from 35S-labeled FVO strain schizont extracts (Fig.
3 A, top arrow). This antiserum also immunoprecipitates a
smaller protein doublet (Fig. 3 A, bottom arrow), at  260
kD and 250 kD, a position at which no PfNBP1 fragments
are routinely seen in immunoblots (see below). An identi-
cal protein doublet is immunoprecipitated by an antiserum
against the PfNBP2a and b shared region (S3), and an anti-
serum against the unique COOH terminus of PfNBP2b
(B). This result suggests that PfNBP1 forms a complex
with at least PfNBP2b, which is consistent with the known
associative properties of the P. vivax PvRBP1 and PvRBP2
proteins (18, 19). In contrast, an antiserum raised against
the unique COOH termini of PfNBP2a (A) did not im-
munoprecipitate any specific bands (Fig. 3 A). Cleavage of
the PfNBP2a during the immunoprecipitation experiment,
despite the presence of protease inhibitors, may remove the
COOH-terminal epitopes against which this antiserum
was raised. Indeed, the 260/250 kD doublet immunopre-
cipitated by the S3 and B antisera is smaller than the full
length product recognized by these antisera by immuno-
blot analysis. Immunoprecipitations with S3 and B antisera
do not reveal a high MW band corresponding to PfNBP1,
but this may be because binding of these antisera disrupts
complex formation.
A Second P. falciparum Strain Expresses a Truncated
PfNBP1. The N1 antiserum was used in immunoblot
analysis of late segmented schizonts extracts from several P.
falciparum strains. In most of the strains examined, FVO,
Dd2, and Malayan Camp K  (Fig. 3 B), and ItG2 and
FCR3 (data not shown), a major high MW protein of
 390 kD was detected, which is slightly larger than the
calculated PfNBP1 MW of 360 kD and the same size as the
high MW band immunoprecipitated by this antiserum
from labeled parasite extracts. A protein band at 220 kD
was occasionally detected in these samples with the N1 an-
tiserum (Fig. 3 B). Preliminary evidence indicates that this
band represents a proteolytic cleavage fragment (data not
shown). The 3D7 strain PfNBP1 protein ( 350 kD) is
slightly smaller than its counterpart in other strains, as pre-
dicted given the single nucleotide insertion in the 3D7
Pfnbp1 gene that causes premature termination of this pro-
tein (Fig. 3 B). Strain 7G8 also expresses a truncated
PfNBP1 product of  310 kD. Importantly, PCR amplifi-
cation of overlapping  2 kb fragments spanning the Pfnbp1
gene from several strains including 7G8 showed no signifi-
cant differences in fragment size between isolates, indicat-
ing the absence of large scale deletions in the Pfnbp1 gene
in 7G8. The observed size of the 7G8 PfNBP1 is consistent
with a mutation  2.3 kb from the 3  end of the gene caus-
ing a truncation of the PfNBP1 product (Fig. 1 C). By
contrast, there were no size differences in PfNBP2a or
PfNBP2b in any of these strains (Fig. 3 C).
PfNBP1 Binds to Erythrocytes. Given their location at
the invasive apical end of the merozoite and homology
with known RBC binding proteins from other Plasmodium
species, we performed EBAs to determine whether the
PfNBPs bound to RBC. [35S]methionine/cysteine labeled
spent merozoite supernatants routinely contained one ma-
jor RBC binding protein (data not shown), which we con-
firmed corresponds to EBA-175 (36, 37). Other smaller
polypeptides also bound the RBCs, but none were in the
300 kD or greater size range as expected for the PfNBPs.
Figure 3. PfNBP1 is a large MW protein that coimmunoprecipitates
with PfNBP2b and varies in size between isolates. (A) 35S-labeled FVO
schizont extracts immunoprecipitated with anti-PfNBP1 antisera (N1),
preimmune antisera (P), or antiserum against shared (S3) or unique (A and
B) regions of PfNBP2a and b, respectively. Anti-PfNBP1 antiserum (N1)
immunoprecipitates a 390-kD band (top arrow) and also a 250/260 kD
doublet (bottom arrow). The doublet is also immunoprecipitated by anti-
sera raised against a region shared by PfNBP2a and b (S3) and the unique
region of PfNBP2b (B). (B) Extracts from late schizont stage synchronized
P. falciparum cultures were separated by SDS PAGE, transferred to nitro-
cellulose and probed with antisera raised against a fragment of PfNBP1
(N1). Culture strains used were FVO (F), 3D7 (3), 7G8 (7), Dd2 (D), and
MC K  (M). The size of the PfNBP1 product differs between strains. (C)
Extracts as in B were probed with an antiserum against a region shared by
PfNBP2a and b (S3), showing no size difference between strains.1576 P. falciparum PvRBP Homologues and Erythrocyte Invasion
However, when samples were immunoblotted with anti-
PfNBP1 antiserum, a fragment of PfNBP1 of  220 kD
was visible in the supernatant that bound equally well to
both unfractionated RBC and blood enriched for reticulo-
cytes (Fig. 4 A, middle arrow). A smaller fragment of
PfNBP1, also visible in the supernatant (Fig. 4 A, bottom
arrow) did not bind to the RBCs. The 220-kD PfNBP1
fragment detected in culture supernatants is the same size as
a PfNBP1 fragment identified in whole parasite extracts
(Fig. 3 B). The larger, faint band detected by the N1 anti-
serum (Fig. 4 A, top arrow) is due to cross-reaction of the
N1 antiserum with an unrelated protein released from
RBCs upon elution with high salt, as it was also visible in
mock EBAs (M) performed without culture supernatants.
RBCs were treated with enzymes in several independent
experiments to further characterize the erythrocyte recep-
tor recognized by PfNBP1. PfNBP1 binding was pre-
vented by treatment with neuraminidase (N), indicating
that adhesion is dependent on sialic acid residues on the
RBC surface, but was unaffected by trypsin (T) treatment
(Fig. 4 B). In contrast, EBA-175 binding was affected by
both neuraminidase and trypsin treatment, confirming that
trypsin treatment had been sufficient to cleave Glycophorin
A residues (Fig. 4 B). Pf240 is detectable in culture super-
natants but does not bind RBCs (Fig. 4 B). PfNBP1 cannot
therefore be binding to Glycophorins A, C, or D, which
are all trypsin sensitive, or Receptor X, which is neuramini-
dase resistant, yet PfNBP1 clearly binds to some proteina-
ceous receptor, as adhesion was inhibited by treatment
with Pronase (P) (Fig. 3 B).
The only known invasion receptor that would fit this
profile is Glycophorin B, which is modified with sialic acid
residues, but in contrast to Glycophorins A, C, and D, is
not cleaved by trypsin. We therefore performed EBAs us-
ing erythrocytes from donors that lack Glycophorin B
(S-s-U ). Surprisingly, PfNBP1 was still able to bind to
these cells (Fig. 4 B). This result was confirmed using sev-
eral different culture supernatant preparations. The S-s-U 
cells were confirmed to be Glycophorin B negative by im-
munoblotting erythrocyte ghosts with an antiserum that
recognizes both Glycophorins A and B (Fig. 4 C). The
PfNBP1 receptor is clearly trypsin resistant and neuramini-
dase sensitive, but does not appear to be one of the previ-
ously characterized invasion receptors. We refer to it
henceforth as Receptor Y.
P. falciparum Strains that Express Truncated PfNBP1 Are
Unable to Invade Trypsinized Erythrocytes. It is well estab-
lished that P. falciparum strains differ in their invasion phe-
notypes. The two P. falciparum strains that express truncated
PfNBP1 proteins, 3D7 and 7G8, still express the majority
of the PfNBP1 protein yet lack the TMD and cytoplasmic
domain. This type of mutation is very similar to the re-
cently reported partial disruption of EBA-175, which re-
sulted in a protein lacking its COOH terminus. This pro-
tein was still expressed and localized correctly, but the
resulting parasite had a severely debilitated ability to invade
RBCs. (15). We therefore performed invasion assays with
five strains of P. falciparum, comparing invasion rates into
untreated erythrocytes versus erythrocytes treated with
neuraminidase, trypsin, and neuraminidase plus trypsin to
define the invasion phenotype of each strain (Table I). In-
vasion of trypsin-treated cells is always substantially lower
than that of untreated cells, but of the two strains express-
ing truncated PfNBP1, 7G8 was completely unable to in-
vade trypsinized cells, and 3D7 did at a extremely reduced
level. FVO, HB3, and Malayan Camp K , all of which ex-
press full-length PfNBP1, are readily able to invade
trypsinized cells. By contrast, invasion of neuraminidase-
treated cells showed no correlation with the presence or
absence of Pfnbp1 mutations. Thus, two strains isolated at
quite different times and places and with two different mu-
tations in the Pfnbp1 gene, are both unable to invade
Figure 4. A fragment of PfNBP1 binds to a trypsin-sensitive receptor
on the erythrocyte surface distinct from Glycophorin B. (A) EBAs using
spent culture supernatants from P. falciparum FVO strain parasites. Bound
material eluted from erythrocytes was immunoblotted with anti-PfNBP1
or anti-EBA-175 antisera. Lanes are starting supernatant (s/n), material
bound to normal erythrocytes ( ), material released from erythrocytes in
the absence of culture supernatant (M), and material bound to erythro-
cytes enriched to  10% reticulocytes (R). (B) EBAs using untreated
erythrocytes ( ); erythrocytes treated with neuraminidase (N), trypsin
(T), both enzymes (N/T) or Pronase (P); or S-s-U  erythrocytes (S).
Eluted material was immunoblotted with either PfNBP1 or EBA-175 an-
tisera, or the mouse Pf240 mAb. (C) Erythrocyte ghosts from a Glyco-
phorin B–positive donor ( ) or a Glycophorin B–negative (S-s-U ) do-
nor (S) immunoblotted with an antiserum recognizing Glycophorin A
and B monomers, homodimers, and heterodimers.1577 Rayner et al.
trypsinized cells. This implies a role for PfNBP1 in a
trypsin resistant invasion pathway, consistent with our pre-
vious findings that the PfNBP1 receptor is trypsin resistant.
Trypsinized erythrocytes had been previously proposed
to have only Glycophorin B as a potential invasion recep-
tor, as strains that are able to invade trypsinised erythrocytes
are unable to invade trypsinized S-s-U  erythrocytes,
where Glycophorin B is absent (1). Indeed, our experi-
ments showed similar results with both FVO and HB3,
which can invade trypsinized cells, but are unable to invade
trypsinized S-s-U  cells (Table I). However, there are
other interpretations of these results, which will be dis-
cussed further below. Surprisingly, 7G8 was completely
unable to invade untreated S-s-U  cells, in two separate
experiments and when other strains cultured in parallel in-
vaded S-s-U  cells efficiently (Table I). 7G8 therefore ap-
pears to be dependent on Glycophorin B for invasion, a
phenotype not previously reported for a P. falciparum strain.
Antibodies Raised against PfNBP1, PfNBP2a, and
PfNBP2b Inhibit Erythrocyte Invasion. To confirm a role
for PfNBP1 in a trypsin resistant invasion pathway, we per-
formed invasion inhibition assays with IgG purified from
the PfNBP1 and the PfNBP2a and PfNBP2b antisera, us-
ing a range of different P. falciparum strains and erythrocytes
that had been modified with different enzyme treatments.
None of the IgG had any affect on invasion of untreated
cells when strains were used that were able to invade
trypsinized erythrocytes (FVO, HB3, and MC K ; Table
II). However, if the targeted RBCs were first trypsinized,
the IgG all had a marked effect on invasion rates at a con-
centration of 1 mg/ml, although the impact of different
IgGs differed somewhat between strains. For example, 1
mg/ml of anti-PfNBP1 IgGs reduced invasion by 31 to
55% depending on the strain (Table II). Although we have
been unable to show that either PfNBP2a or PfNBP2b
bind to erythrocytes, antibodies raised against a region
shared by both molecules (S3) or regions unique to each (A
or B) all inhibited invasion of trypsinized cells. Anti-
PfNBP1 and PfNBP2 IgG do not impact the sialic acid-
independent, Receptor X pathway, as they had no effect
on invasion of HB3 merozoites into neuraminidase-treated
cells (data not shown). The PfNBPs clearly play a role in a
trypsin-resistant invasion pathway.
Unlike all other strains tested, invasion of 3D7 parasites
into untreated erythrocytes is inhibited by  -PfNBP1,
 -PfNBP2a, and  -PfNBP2b IgG. Furthermore, when
 -PfNBP1 IgG and  -PfNBP2 IgG were mixed we ob-
served a greater level of inhibition of invasion than with ei-
ther IgG alone, supporting a cooperative model of invasion
(data not shown). Other researchers had noted that  -PfNBP2
IgG can inhibit 3D7 invasion (22), but the antiserum in that
case was not specific to either PfNBP2a or PfNBP2b. We
show clearly here that all three PvRBP homologs (PfNBP1,
PfNBP2a, and PfNBP2b) are involved in invasion.
Discussion
We have identified a P. falciparum ortholog of the P.
vivax reticulocyte binding protein, PvRBP1, and present
evidence that this protein, PfNBP1, is the parasite ligand
for an unknown, trypsin-resistant invasion receptor, Re-
ceptor Y. PfNBP1 binds to erythrocytes, and this adhesion
is dependent on a neuraminidase-sensitive, trypsin-resistant
Table I. Plasmodium falciparum Strains Expressing Truncated 
PfNBP1 Are Unable to Invade Trypsinized RBCs
Pf
strain
Neura-
minidase Trypsin Neura./Tryp S-s-U  Tryp/S-s-U 
FVO 4   1 30   72     1 79   40  
HB3 69   19 38   17 1   1 77   16     4
MC K  16   6 31   47     3N D N D
3D7 30   75     5 0 73   62     2
7G8 47   62     103     30
Purified P. falciparum schizonts from strains listed were incubated with
erythrocytes treated with neuraminidase, trypsin, or both (Neura./
Tryp). Glycophorin B-negative cells (S-s-U ) were also used. Invasion
rates are expressed as a percentage of the invasion into untreated
erythrocytes, with standard error.
Table II. Antisera Against Plasmodium falciparum Normocyte Binding Proteins Inhibit Merozoite Invasion of Trypsinized RBCs
PF strain Treatment Prebleed NBP1 NBP2 (S3) NBP2a NBP2b
FVO None 106   7 102   15 107   25 114   4 104   7
FVO Trypsin 107   7 45   2 65   2 65   1 68   12
HB3 None 94   2 100   1 110   13 104   17 95   1
HB3 Trypsin 96   3 69   17 45   15 66   14 26   10
MC K  None 118   18 94   5 139   7N D N D
MC K  Trypsin 122   7 60   12 43   6N D N D
3D78 None 95   7 50   1 51   3 57   7 70   6
Purified schizonts were incubated with untreated erythrocyte or trypsin-treated erthrocytes (T) in the presence of purified IgG. IgG was added at 1
mg/ml and invasion rates are expressed as a percentage of invasion in the absence of any IgG, with standard error.1578 P. falciparum PvRBP Homologues and Erythrocyte Invasion
factor distinct from Glycophorin B on the erythrocyte sur-
face. An antiserum against PfNBP1 inhibits P. falciparum in-
vasion of erythrocytes via a trypsin-resistant pathway, and
P. falciparum strains expressing truncated PfNBP1 are un-
able to invade trypsinized erythrocytes.
Immunoprecipitation data further suggests that PfNBP1
and PfNBP2b may form a complex, as was shown for the
P. vivax reticulocyte binding proteins (18, 19). The P. vivax
RBP1 and RBP2 proteins can be coimmunoprecipitated
using both 35S-labeled culture supernatants or in vitro trans-
lated fragments of each protein (18, 19; unpublished data).
The formation of a similar protein complex in P. falciparum
could explain the inhibitory effect of PfNBP2 antisera on
invasion despite the lack of detectable adhesion of PfNBP2
to RBCs (Table II). Specific IgG raised against either shared
or unique regions of PfNBP2a and 2b inhibit invasion of
trypsinized cells by FVO, HB3, and MC K  parasites, argu-
ing strongly that both are involved in the same trypsin-
resistant pathway as PfNBP1. Further evidence of cooper-
ativity between PfNBP1 and the PfNBP2s is shown by a
greater effect on invasion when IgGs against these proteins
are mixed than either IgG alone (data not shown). The
functional significance of a potential PfNBP1-PfNBP2
complex and the relative contributions of PfNBP2a and 2b
are details that remain to be established.
The PvRBP Superfamily. Gene structure, amino acid
homology, phylogeny modeling, and erythrocyte binding
analyses all support the proposal that the P. vivax RBPs, the
P. falciparum NBPs, and the P. yoelii p235 rhoptry proteins
form a super-family of related molecules (20–23, 33).
While PvRBP1 and PvRBP2 share several features, they
are not highly conserved at the amino acid level and, in
fact, were originally viewed as two distinct proteins rather
than as paralogues (18). We show here via phylogenetic
and other analyses that PfNBP1 and PfNBP2a/2b are in
fact respective homologs of these two proteins. Further, the
reported P. yoelii p235 rhoptry proteins are evolutionarily
related to PvRBP-2 and the PfNBP2 proteins. The data
corroborate the fact that these proteins comprise a super-
family of two distinct subfamilies, PvRBP1-like molecules
and PvRBP2-like molecules. In line with this, there is one
other P. falciparum gene that is a paralogue to Pfnbp1 and
several simian malarias also have distinct PvRBP1-like and
PvRBP2-like homologs (unpublished data). Although a
family of PvRBP2-like molecules is known to play a role
in invasion in the rodent malaria, P. yoelii, it is not yet
known if a PvRBP1 ortholog or homologs exists in this
distantly related species of Plasmodium. The situation in P.
yoelii is somewhat unique given the large size of the p235
family and that each merozoite from a single schizont may
express a different member of the family (38). At this stage,
no such extensive family appears to exist in P. falciparum.
The binding specificities of different members of the
PvRBP superfamily clearly differ. PfNBP1 has no prefer-
ence to bind reticulocytes, whereas the PvRBPs were ini-
tially identified by their reticulocyte binding properties
(18). Similarly, PfNBP1 binding is dependent on sialic acid,
whereas binding of the P. yoelii p235 family is unaffected
by neuraminidase (39). This is not unexpected given the
evolutionary distance between these Plasmodium species
and the different niches of parasitism they exploit in RBC
lineage, and is akin to the erythrocyte binding-like (EBL)
or, more appropriately termed, Duffy binding-like (DBL)
invasion ligand super-family (13, 40). The P. vivax and P.
knowlesi Duffy binding proteins bind to the peptide back-
bone of the Duffy glycoprotein (41, 42), while P. falciparum
EBA-175 ligand primarily recognizes sialic acid residues on
Glycophorin A (14), yet are still classified together, along
with other paralogues, in the DBL family by structure and
sequence relatedness (13, 40). As a parallel to the DBL clas-
sification, the PvRBPs and their respective homologs
might best be referred to as the reticulocyte binding-like
(RBL) superfamily.
The Nature of Receptor Y. Although we have established
that the receptor recognized by PfNBP1 is a protein that
contains sialic acid residues and is resistant to trypsin, no
immediate candidates for the receptor on RBC surface are
evident. Of the major rbc sialoglycoproteins, the glycophor-
ins, only Glycophorin B is trypsin resistant, and PfNBP1
is able to bind erythrocytes that lack Glycophorin B. The
presence of a second, neuraminidase-sensitive, trypsin-
resistant receptor is unexpected, but not entirely unprece-
dented. The Malayan Camp K  strain is able to invade, al-
beit at a lower level, trypsinised MkMk cells, which through
mutation lack both Glycophorin A and B and through
trypsinization lack Receptor X and Glycophorins C and D
as well (9). The invasion pathway used by MC K  parasites
in this case is neuraminidase sensitive and trypsin resistant,
just like Receptor Y. Given the extreme rarity of MkMk
cells, the possibility of this unknown receptor matching
Receptor Y could not be tested.
Although the identity of Receptor Y is unknown, the
invasion data infers that Receptor Y and Glycophorin B
may function in similar ways or at similar points during in-
vasion. We and others have noted that strains that are able
to invade trypsinised erythrocytes are unable to invade
trypsinised S-s-U  erythrocytes. One explanation for this is
that Receptor Y is necessary but not sufficient for invasion
using a common trypsin-resistant pathway. Hence, strains
with Pfnbp1 mutations unable to utilize Receptor Y are
unable to invade trypsinised cells and antibodies raised
against PfNBP1 can inhibit the invasion of trypsinised cells
(PfNBP1 is necessary for invasion using this pathway), but
strains that posses functional PfNBP1 are unable to invade
using it alone, as in trypsinised S-s-U  cells (PfNBP1 is not
sufficient for invasion).
Implications for Models of Erythrocyte Invasion. If PfNBP1
contributes to invasion via a trypsin-resistant pathway,
does this constitute a distinct, alternative invasion route?
The phrase “alternative” pathways may not be the most
helpful to our understanding of invasion. As others have
mentioned (1), invasion pathways could operate in series
or in parallel. That is, they could function only indepen-
dently of one another or they may routinely function to-
gether but can be forced to function in isolation when host
cells are enzymatically manipulated or selection pressure is1579 Rayner et al.
applied. An integrated model appears more likely. Where
the number of available receptors has been restricted by
enzymatic modification, invasion is almost always less effi-
cient than invasion of untreated cells, arguing against
strictly independent alternative invasion pathways. Fur-
thermore, two strains that are able to invade using the
same “alternative” pathway can do so at quite different ef-
ficiencies, implying that the ability to exploit a particular
pathway is not always the result of the simple presence or
absence of a single parasite ligand.
We think it likely that PfNBP1 and the trypsin-resistant
pathway routinely play a specific role during the invasion
of untreated erythrocytes and only inefficiently and in ex-
tremis function in isolation. Although IgG raised against
PfNBP1, PfNBP2a, and PfNBP2b all had no affect on the
invasion of untreated cells by FVO, HB3, and MC para-
sites, they did affect the invasion of 3D7 parasites into un-
treated cells, clearly implying a role for PfNBP1 in invasion
of untreated erythrocytes in this strain. A broadly similar
result was seen previously with a single PfNBP2 antisera,
where invasion was affected in 3D7 parasites but not an-
other strain, D10 (22). In that instance it was proposed that
this difference might result from sequence divergence be-
tween the PfNBP2 genes in the different strains, although
few such differences were detected (22). In this study we
found several different antisera were effective against a
range of different strains, making the former explanation
unlikely. Given the mutation in the Pfnbp1 gene observed
in 3D7, the expressed PfNBP1 product may be partially
functional, but sufficiently compromised, to be relatively
easily inhibited by antibodies, whereas in other strains with
a fully functional PfNBP1, the trypsin-resistant pathway
may be much more difficult to inhibit (perhaps because of
the overlapping roles of Receptor Y and Glycophorin B
discussed above). A disruption of the Pfnbp1 gene causing
the complete absence of PfNBP1, if such a phenotype were
viable, would be the test for the role of this ligand in the
invasion of untreated cells. Extensive selection of transfor-
mants with a Pfnbp1 disruption plasmid in our laboratory
has not produced any disruptants, suggesting that the gene
may be recalcitrant to this type of genetic manipulation
(data not shown).
If PfNBP1 does play a role in the invasion of erythro-
cytes, what is that role? EBA-175, through its familial rela-
tionship to the Duffy binding proteins of P. vivax and P.
knowlesi, has been implicated in the formation of the elec-
tron-dense tight junction between the apical end of the
merozoite and the erythrocyte membrane, a relatively late
and irreversible step in the invasion cascade (43). A location
of PfNBP1 at the apical surface of the merozoite could im-
ply that it may function just before EBA-175, which is se-
questered in the micronemes (35) and must be released
from this internal location before interaction with the
erythrocyte surface is possible. One model, based previ-
ously on invasion properties of P. vivax, proposed PvRBP1
and PvRBP2 function early in the invasion cascade, select-
ing reticulocytes for invasion and triggering the release of
the contents of the micronemes which includes the P. vivax
homologue of EBA-175, the Duffy binding protein (18,
19). Unlike P. vivax, P. falciparum shows no striking prefer-
ence for subpopulations of erythrocytes. Nevertheless, in
parallel with the hypothesis about the function(s) of the
PvRBPs, PfNBP1 and the trypsin-resistant pathway may
also play a role in this early step by recognizing Receptor Y
and potentially inducing a signal to begin the invasion cas-
cade, through release of EBA-175 and its paralogues.
Erythrocyte invasion by P. falciparum merozoites is a
complex and incompletely understood process. Any vac-
cine designed to prevent erythrocyte invasion must reflect
this complicated reality and include the ligands for all po-
tential invasion pathways. Deployment of a vaccine of lim-
ited inclusiveness will risk the application of strong selec-
tion pressures, allowing parasite populations to switch from
one pathway to another and to varying degrees escape the
induced immunity. As the ligand for a trypsin-resistant
pathway, PfNBP1, and perhaps its partners PfNBP2a and
2b, clearly merit further study in regards to function and
certainly consideration as candidates for inclusion in any in-
vasion blocking vaccine.
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